Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: CD5
Name: CD5 molecule
Location: 11q12.2
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT00481858 Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis View
NCT00566332 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia View
NCT00926692 Investigations Regarding B-cell Subsets in Humans View
NCT01453062 Phase IV Observational Study in Chronic Lymphocytic Leukemia View
NCT02833285 B Cell Functions in Periodontitis View
NCT03081910 Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen View
NCT04300101 Mixed Molecular Clinical Index MMCI in Diffuse Large B-cell Lymphoma DLBCL View
NCT04411043 Observatory of Prolymphocytic Leukemia T View
NCT01110850 Direct Measurement of Leukemic Cell Turnover Synthesis and Removal in Patients With Chronic Lymphocytic Leukemia CLL Using Deuterated Water View
NCT00143065 Fludarabine Rituximab and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma View
NCT04767308 Safety and Efficacy of CT125A Cells for Treatment of RelapsedRefractory CD5 Hematopoietic Malignancies View
NCT05032599 Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia View
NCT05487495 Donor-Derived CD5 CAR T CT125B Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic LeukemiaLymphoma View
NCT06316856 CD5 Chimeric Antigen Receptor CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia View
NCT06420089 CD5-deleted Chimeric Antigen Receptor Cells Senza5 CART5 for T Cell Non-Hodgkin Lymphoma NHL View
NCT06420076 Sequential CAR-T Cells Therapy for CD5CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5CD7-Specific CAR-T Cells View
NCT05110742 Phase III Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of RelapsedRefractory Hematological Malignances View
NCT04594135 Anti-CD5 CAR T Cells for RelapsedRefractory T Cell Malignancies View
NCT05138458 A Study of MT-101 in Subjects With CD5 RelapsedRefractory TCL View
NCT06647940 Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL PatientsRocket Trial View
NCT05590702 French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings View
NCT05596266 CD5 CAR-T Therapy for RefractoryRelapsed CD5 T-cell Acute Lymphoblastic Leukemia View
NCT06633341 Targeting CD5 CAR-T Cells in the Treatment of rr CD5 T-lymphoma View
NCT06633354 Targeting CD5 CAR-T Cells in the Treatment of rr CD5 T-ALL View
NCT06534060 MB-105 in Patients With CD5 Positive T-cell Lymphoma View
NCT00117156 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkins Lymphoma View
NCT00925925 Epigenetic Markers of B-Cell Function in Low Birth Weight Infants View
NCT02853370 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma View
NCT03906227 Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive CD5 Regulatory B Cell Recovery in ANCA Vasculitis View